Une ostéonécrose iatrogène
Actualités Pharmaceutiques, ISSN: 0515-3700, Vol: 58, Issue: 584, Page: 56-57
2019
- 1Citations
- 1Captures
Metric Options: CountsSelecting the 1-year or 3-year option will change the metrics count to percentiles, illustrating how an article or review compares to other articles or reviews within the selected time period in the same journal. Selecting the 1-year option compares the metrics against other articles/reviews that were also published in the same calendar year. Selecting the 3-year option compares the metrics against other articles/reviews that were also published in the same calendar year plus the two years prior.
Example: if you select the 1-year option for an article published in 2019 and a metric category shows 90%, that means that the article or review is performing better than 90% of the other articles/reviews published in that journal in 2019. If you select the 3-year option for the same article published in 2019 and the metric category shows 90%, that means that the article or review is performing better than 90% of the other articles/reviews published in that journal in 2019, 2018 and 2017.
Citation Benchmarking is provided by Scopus and SciVal and is different from the metrics context provided by PlumX Metrics.
Example: if you select the 1-year option for an article published in 2019 and a metric category shows 90%, that means that the article or review is performing better than 90% of the other articles/reviews published in that journal in 2019. If you select the 3-year option for the same article published in 2019 and the metric category shows 90%, that means that the article or review is performing better than 90% of the other articles/reviews published in that journal in 2019, 2018 and 2017.
Citation Benchmarking is provided by Scopus and SciVal and is different from the metrics context provided by PlumX Metrics.
Metrics Details
- Citations1
- Citation Indexes1
- CrossRef1
- Captures1
- Readers1
Review Description
L’ostéonécrose est une dégradation anormale et prématurée d’un tissu osseux due à un défaut de vascularisation. La maladie touche principalement des os longs comme le fémur mais aussi des os courts. Il existe de nombreuses causes à cette pathologie qui peut être induite par des médicaments comme les bisphosphonates. Un cas de pharmacovigilance avec le bévacizumab utilisé dans un contexte de cancer du sein a été signalé. Osteonecrosis is the abnormal and premature deterioration of bone tissue due to an interruption of the blood supply. The disease mainly affects long bones such as the femur but can also affect short bones. There are a number of causes of this condition which can be induced by medicines such as bisphosphonates. A pharmacovigilance case report flagged an adverse event with bevacizumbab used to treat breast cancer.
Bibliographic Details
http://www.sciencedirect.com/science/article/pii/S0515370019300503; http://dx.doi.org/10.1016/j.actpha.2019.01.021; http://www.scopus.com/inward/record.url?partnerID=HzOxMe3b&scp=85063290452&origin=inward; https://linkinghub.elsevier.com/retrieve/pii/S0515370019300503; https://api.elsevier.com/content/article/PII:S0515370019300503?httpAccept=text/xml; https://api.elsevier.com/content/article/PII:S0515370019300503?httpAccept=text/plain; https://dul.usage.elsevier.com/doi/; https://dx.doi.org/10.1016/j.actpha.2019.01.021
Elsevier BV
Provide Feedback
Have ideas for a new metric? Would you like to see something else here?Let us know